G. M. Mckhann, D. S. Knopman, H. Chertkow, B. T. Hyman, C. R. Jack et al., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement. J. Alzheimers Assoc, vol.7, pp.263-269, 2011.

M. S. Albert, S. T. Dekosky, D. Dickson, B. Dubois, H. H. Feldman et al., The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement. J. Alzheimers Assoc, vol.7, pp.270-279, 2011.

R. A. Sperling, P. S. Aisen, L. A. Beckett, D. A. Bennett, S. Craft et al., Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement. J. Alzheimers Assoc, vol.7, pp.280-292, 2011.

C. R. Jack, M. Albert, D. S. Knopman, G. M. Mckhann, R. A. Sperling et al., Introduction to Revised Criteria for the Diagnosis of Alzheimer's Disease: National Institute on Aging and the Alzheimer Association Workgroups, Alzheimers Dement. J. Alzheimers Assoc, vol.7, pp.257-262, 2011.

B. Dubois, H. H. Feldman, C. Jacova, H. Hampel, J. L. Molinuevo et al., Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria, Lancet Neurol, vol.13, pp.614-629, 2014.

C. R. Jack, D. A. Bennett, K. Blennow, M. C. Carrillo, H. H. Feldman et al., A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers, Neurology, vol.87, pp.539-547, 2016.

F. Hulstaert, K. Blennow, A. Ivanoiu, H. C. Schoonderwaldt, M. Riemenschneider et al., Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF, Neurology, vol.52, pp.1555-1562, 1999.

B. Olsson, R. Lautner, U. Andreasson, A. Öhrfelt, E. Portelius et al., CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis, Lancet Neurol, vol.15, pp.673-684, 2016.

K. Buerger, M. Ewers, T. Pirttilä, R. Zinkowski, I. Alafuzoff et al., CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease, vol.129, pp.3035-3041, 2006.

T. T. Seppälä, O. Nerg, A. M. Koivisto, J. Rummukainen, L. Puli et al., CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings, Neurology, vol.78, pp.1568-1575, 2012.

D. Strozyk, K. Blennow, L. R. White, and L. J. Launer, CSF Abeta 42 levels correlate with amyloidneuropathology in a population-based autopsy study, Neurology, vol.60, pp.652-656, 2003.

S. Engelborghs, D. Vreese, K. Van-de-casteele, T. Vanderstichele, H. Van-everbroeck et al., Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia, Neurobiol. Aging, vol.29, pp.1143-1159, 2008.

O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow et al., Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, Lancet Neurol, vol.5, pp.228-234, 2006.

A. J. Mitchell, CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies, J. Neurol. Neurosurg. Psychiatry, vol.80, pp.966-975, 2009.

C. Hesse, L. Rosengren, N. Andreasen, P. Davidsson, H. Vanderstichele et al., Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, Neurosci. Lett, vol.297, pp.187-190, 2001.

A. De-wilde, I. S. Van-maurik, M. Kunneman, F. Bouwman, M. Zwan et al., Alzheimer's biomarkers, 2017.

, Alzheimers Dement. Diagn. Assess. Dis. Monit, vol.6, pp.143-151

G. B. Frisoni, N. C. Fox, C. R. Jack, P. Scheltens, and P. M. Thompson, The clinical use of structural MRI in Alzheimer disease, Nat. Rev. Neurol, vol.6, pp.67-77, 2010.

D. Sole, A. Malaspina, S. Biasina, and A. M. , Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias, Funct. Neurol, vol.31, pp.205-215, 2017.

D. Silverman, G. W. Small, C. Y. Chang, C. S. Lu, M. Aburto et al., Positron Emission Tomography in Evaluation of Dementia: Regional Brain Metabolism and Long-term Outcome, JAMA, vol.286, pp.2120-2127, 2001.

M. B. Patwardhan, D. C. Mccrory, D. B. Matchar, G. P. Samsa, and O. T. Rutschmann, Alzheimer disease: operating characteristics of PET-a meta-analysis, Radiology, vol.231, pp.73-80, 2004.

S. L. Risacher and A. J. Saykin, Neuroimaging and Other Biomarkers for Alzheimer's Disease: The Changing Landscape of Early Detection, Annu. Rev. Clin. Psychol, vol.9, pp.621-648, 2013.

C. R. Jack, D. S. Knopman, W. J. Jagust, R. C. Petersen, M. W. Weiner et al., Update on hypothetical model of Alzheimer's disease biomarkers, Lancet Neurol, vol.12, pp.207-216, 2013.

A. Caroli and G. B. Frisoni, The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort, Neurobiol. Aging, vol.31, pp.1263-1274, 2010.

K. Meguro, C. Lemestric, B. Landeau, B. Desgranges, F. Eustache et al., Relations between hypometabolism in the posterior association neocortex and hippocampal atrophy in Alzheimer's disease: a PET/MRI correlative study, J. Neurol. Neurosurg. Psychiatry, vol.71, pp.315-321, 2001.

D. Santi, S. De-leon, M. J. Rusinek, H. Convit, A. Tarshish et al., Hippocampal formation glucose metabolism and volume losses in MCI and AD, Neurobiol. Aging, vol.22, pp.529-539, 2001.

D. S. Karow, L. K. Mcevoy, C. Fennema-notestine, D. J. Hagler, R. G. Jennings et al., Relative Capability of MR Imaging and FDG PET to Depict Changes Associated with Prodromal and Early Alzheimer Disease, Radiology, vol.256, pp.932-942, 2010.

M. F. Folstein, S. E. Folstein, and P. R. Mchugh, Mini-mental state": A practical method for grading the cognitive state of patients for the clinician, J. Psychiatr. Res, vol.12, pp.189-198, 1975.

D. De-jong, R. Jansen, B. Kremer, and M. M. Verbeek, Cerebrospinal Fluid Amyloid ?42/Phosphorylated Tau Ratio Discriminates Between Alzheimer's Disease and Vascular Dementia, J. Gerontol. Ser. A, vol.61, pp.755-758, 2006.

F. Tabaraud, J. P. Leman, A. M. Milor, J. M. Roussie, G. Barrière et al., Alzheimer CSF biomarkers in routine clinical setting, Acta Neurol. Scand, vol.125, pp.416-423, 2012.

A. Aziz, B. Giusiano, S. Joubert, L. Duprat, M. Didic et al., Difference in imaging biomarkers of neurodegeneration between early and late-onset amnestic Alzheimer's disease, Neurobiol. Aging, vol.54, pp.22-30, 2017.

, R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2017.

A. Fellgiebel, T. Siessmeier, A. Scheurich, G. Winterer, P. Bartenstein et al., Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxyD-glucose positron emission tomography findings in patients with mild cognitive impairment, Biol. Psychiatry, vol.56, pp.279-283, 2004.

R. Ceravolo, D. Borghetti, L. Kiferle, G. Tognoni, A. Giorgetti et al., CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease, Brain Res. Bull, vol.76, pp.80-84, 2008.

L. Mosconi, D. Santi, S. Brys, M. Tsui, W. H. Pirraglia et al., Hypometabolism and Altered Cerebrospinal Fluid Markers in Normal Apolipoprotein E E4 Carriers with Subjective Memory Complaints, Biol. Psychiatry, vol.63, pp.609-618, 2008.

W. J. Jagust, S. M. Landau, L. M. Shaw, J. Q. Trojanowski, R. A. Koeppe et al., Relationships between biomarkers in aging and dementia, vol.73, pp.1193-1199, 2009.

A. D. Cohen, J. C. Price, L. A. Weissfeld, J. James, B. L. Rosario et al., Basal Cerebral Metabolism May Modulate the Cognitive Effects of A? in Mild Cognitive Impairment: An Example of Brain Reserve, J. Neurosci. Off. J. Soc. Neurosci, vol.29, p.14770, 2009.

R. Ossenkoppele, D. R. Schonhaut, M. Schöll, S. N. Lockhart, N. Ayakta et al., PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease, Brain, vol.139, pp.1551-1567, 2016.

G. N. Bischof, F. Jessen, K. Fliessbach, J. Dronse, J. Hammes et al., Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease, Ann. Clin. Transl. Neurol, vol.3, pp.934-939, 2016.

K. Chiotis, L. Saint-aubert, I. Savitcheva, V. Jelic, P. Andersen et al., Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm, Eur. J. Nucl. Med. Mol. Imaging, vol.43, pp.1686-1699, 2016.

C. Haense, K. Buerger, E. Kalbe, A. Drzezga, S. J. Teipel et al., CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease, Eur. J. Neurol, vol.15, pp.1155-1162, 2008.

H. Braak and E. Braak, Neuropathological stageing of Alzheimer-related changes, Acta Neuropathol. (Berl.), vol.82, pp.239-259, 1991.

A. Delacourte, J. P. David, N. Sergeant, L. Buée, A. Wattez et al., The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease, Neurology, vol.52, pp.1158-1165, 1999.

A. M. Fagan, D. Head, A. R. Shah, D. Marcus, M. Mintun et al., Decreased CSF A?42 correlates with brain atrophy in cognitively normal elderly, Ann. Neurol, vol.65, pp.176-183, 2009.

X. Li, T. Li, N. Andreasen, M. K. Wiberg, E. Westman et al., The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease, J. Intern. Med, vol.275, pp.418-427, 2014.

L. Wahlund and K. Blennow, Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients, Neurosci. Lett, vol.339, pp.99-102, 2003.

G. Chételat, V. L. Villemagne, K. E. Pike, J. Baron, P. Bourgeat et al., Larger temporal volume in elderly with high versus low beta-amyloid deposition, Brain, vol.133, pp.3349-3358, 2010.

A. Foubert-samier, G. Catheline, H. Amieva, B. Dilharreguy, C. Helmer et al., Education, occupation, leisure activities, and brain reserve: a population-based study, Neurobiol. Aging, vol.33, pp.15-423, 2012.

Y. Liu, V. Julkunen, T. Paajanen, E. Westman, L. Wahlund et al., Education increases reserve against Alzheimer's disease-evidence from structural MRI analysis, Neuroradiology, vol.54, pp.929-938, 2012.

S. W. Seo, K. Im, J. Lee, S. T. Kim, H. J. Ahn et al., Effects of demographic factors on cortical thickness in Alzheimer's disease, Neurobiol. Aging, vol.32, pp.200-209, 2011.

K. Persson, R. S. Eldholm, M. L. Barca, L. Cavallin, D. Ferreira et al., MRI-assessed atrophy subtypes in Alzheimer's disease and the cognitive reserve hypothesis, PLOS ONE, vol.12, 2017.

A. C. Van-loenhoud, A. M. Wink, C. Groot, S. Verfaillie, J. Twisk et al., A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease. Hum, Brain Mapp, vol.38, pp.4703-4715, 2017.

H. Amieva, H. Mokri, L. Goff, M. Meillon, C. Jacqmin-gadda et al., Compensatory mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 years of cognitive decline, Brain, vol.137, pp.1167-1175, 2014.

Y. Stern, Cognitive reserve in ageing and Alzheimer's disease, Lancet Neurol, vol.11, pp.1006-1012, 2012.

N. Scarmeas, S. M. Albert, J. J. Manly, and Y. Stern, Education and rates of cognitive decline in incident Alzheimer's disease, J. Neurol. Neurosurg. Psychiatry, vol.77, pp.308-316, 2006.

G. Chételat, Multimodal Neuroimaging in Alzheimer's Disease: Early Diagnosis, Physiopathological Mechanisms, and Impact of Lifestyle, J. Alzheimers Dis. JAD, 2018.

G. Chételat, B. Desgranges, B. Landeau, F. Mézenge, J. B. Poline et al., Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease, Brain, vol.131, pp.60-71, 2008.

T. Kawachi, K. Ishii, S. Sakamoto, M. Sasaki, T. Mori et al., Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease, Eur. J. Nucl. Med. Mol. Imaging, vol.33, pp.801-809, 2006.

K. Chen, N. Ayutyanont, J. Langbaum, A. S. Fleisher, C. Reschke et al., Correlations between FDG PET glucose uptake-MRI gray matter volume scores and apolipoprotein E ?4 gene dose in cognitively normal adults: a cross-validation study using voxel-based multi-modal partial least squares, Neuroimage, vol.60, pp.2316-2322, 2012.

, A signed Wilcoxon ranks test adjusted with the Bonferroni method was used in case of significance in the Kruskal Wallis test: For atrophy extent: between G3-G1

I. For and G. , G4-G2 (not significant); between G4-G3 (p=0.042) ¤¤: Fisher's exact test

, Alzheimer's Disease and Dementia | Alzheimer's Association

R. N. Kalaria, G. E. Maestre, R. Arizaga, R. P. Friedland, D. Galasko et al., Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors, Lancet Neurol, vol.7, pp.812-826, 2008.

H. Braak and E. Braak, Neuropathological stageing of Alzheimer-related changes, Acta Neuropathol. (Berl.), vol.82, pp.239-259, 1991.

D. R. Thal, U. Rüb, M. Orantes, and H. Braak, Phases of A beta-deposition in the human brain and its relevance for the development of AD, Neurology, vol.58, pp.1791-1800, 2002.

A. Delacourte, J. P. David, N. Sergeant, L. Buée, A. Wattez et al., The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease, Neurology, vol.52, pp.1158-1165, 1999.

C. R. Jack, M. Albert, D. S. Knopman, G. M. Mckhann, R. A. Sperling et al., Introduction to Revised Criteria for the Diagnosis of Alzheimer's Disease: National Institute on Aging and the Alzheimer Association Workgroups, Alzheimers Dement. J. Alzheimers Assoc, vol.7, pp.257-262, 2011.

R. A. Sperling, P. S. Aisen, L. A. Beckett, D. A. Bennett, S. Craft et al., Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement. J. Alzheimers Assoc, vol.7, pp.280-292, 2011.

G. M. Mckhann, D. S. Knopman, H. Chertkow, B. T. Hyman, C. R. Jack et al., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement. J, 2011.

, Alzheimers Assoc, vol.7, pp.263-269

M. S. Albert, S. T. Dekosky, D. Dickson, B. Dubois, H. H. Feldman et al., The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on AgingAlzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement. J. Alzheimers Assoc, vol.7, pp.270-279, 2011.

B. Dubois, H. H. Feldman, C. Jacova, H. Hampel, J. L. Molinuevo et al., Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria, Lancet Neurol, vol.13, pp.614-629, 2014.

, Biomarkers and surrogate endpoints: preferred definitions and conceptual framework, Biomarkers Definitions Working Group, vol.69, pp.89-95, 2001.

, Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group, Neurobiol. Aging, vol.19, pp.109-116

L. Koric, O. Felician, and M. Ceccaldi, Use of CSF biomarkers in the diagnosis of Alzheimer's disease in clinical practice, Rev. Neurol, vol.167, pp.474-484, 2011.

F. Hulstaert, K. Blennow, A. Ivanoiu, H. C. Schoonderwaldt, M. Riemenschneider et al., Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF, Neurology, vol.52, pp.1555-1562, 1999.

K. Blennow and H. Hampel, CSF markers for incipient Alzheimer's disease, Lancet Neurol, vol.2, pp.605-613, 2003.

R. Craig-schapiro, A. M. Fagan, and D. M. Holtzman, Biomarkers of Alzheimer's Disease, Neurobiol. Dis, vol.35, pp.128-140, 2009.

M. Otto, H. Esselmann, W. Schulz-shaeffer, M. Neumann, A. Schröter et al., Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, Neurology, vol.54, pp.1099-1102, 2000.

O. Hansson, H. Zetterberg, P. Buchhave, U. Andreasson, E. Londos et al., Prediction of Alzheimer's disease using the CSF, 2007.

, Abeta42/Abeta40 ratio in patients with mild cognitive impairment, Dement. Geriatr. Cogn. Disord, vol.23, pp.316-320

A. D. Henriques, A. L. Benedet, E. F. Camargos, P. Rosa-neto, and O. T. Nóbrega, Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to, Exp. Gerontol, 2018.

A. J. Mitchell, CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies, J. Neurol. Neurosurg. Psychiatry, vol.80, pp.966-975, 2009.

C. Hesse, L. Rosengren, N. Andreasen, P. Davidsson, H. Vanderstichele et al., Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, Neurosci. Lett, vol.297, pp.187-190, 2001.

P. A. Thomann, E. Kaiser, P. Schönknecht, J. Pantel, M. Essig et al., Association of total tau and phosphorylated tau 181 protein levels in cerebrospinal fluid with cerebral atrophy in mild cognitive impairment and Alzheimer disease, J. Psychiatry Neurosci. JPN, vol.34, pp.136-142, 2009.

F. Tabaraud, J. P. Leman, A. M. Milor, J. M. Roussie, G. Barrière et al., Alzheimer CSF biomarkers in routine clinical setting, Acta Neurol. Scand, vol.125, pp.416-423, 2012.

V. De-riva, E. Galloni, M. Marcon, D. Dionisio, L. Deluca et al., Analysis of combined CSF biomarkers in AD diagnosis, Clin. Lab, vol.60, pp.629-634, 2014.

D. De-jong, R. Jansen, B. Kremer, and M. M. Verbeek, Cerebrospinal Fluid Amyloid ?42/Phosphorylated Tau Ratio Discriminates Between Alzheimer's Disease and Vascular Dementia, J. Gerontol. Ser. A, vol.61, pp.755-758, 2006.

N. Mattsson, H. Zetterberg, O. Hansson, N. Andreasen, L. Parnetti et al., CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment, vol.302, pp.385-393, 2009.

L. M. Shaw, M. Korecka, C. M. Clark, V. Lee, and J. Q. Trojanowski, Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics, Nat. Rev. Drug Discov, vol.6, pp.295-303, 2007.

A. M. Fagan, C. M. Roe, C. Xiong, M. A. Mintun, J. C. Morris et al., Cerebrospinal Fluid tau/?-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults, Arch. Neurol, vol.64, pp.343-349, 2007.

S. E. Counts, M. D. Ikonomovic, N. Mercado, I. E. Vega, and E. J. Mufson, Biomarkers for the Early Detection and Progression of Alzheimer's Disease, Neurotherapeutics, vol.14, pp.35-53, 2017.

G. Li, I. Sokal, J. F. Quinn, J. B. Leverenz, M. Brodey et al., CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study, Neurology, vol.69, pp.631-639, 2007.

T. Tapiola, I. Alafuzoff, S. Herukka, L. Parkkinen, P. Hartikainen et al., Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain, Arch. Neurol, vol.66, pp.382-389, 2009.

A. K. Wallin, K. Blennow, H. Zetterberg, E. Londos, L. Minthon et al., CSF biomarkers predict a more malignant outcome in Alzheimer disease, Neurology, vol.74, pp.1531-1537, 2010.

A. Drzezga, Diagnosis of Alzheimer’s Disease with [18F]PET in Mild and Asymptomatic Stages, Behav. Neurol, vol.21, pp.101-115, 2009.

H. Hampel, K. Bürger, S. J. Teipel, A. Bokde, H. Zetterberg et al., Core candidate neurochemical and imaging biomarkers of Alzheimer's disease?, Alzheimers Dement, vol.4, pp.38-48, 2008.

L. Mosconi, V. Berti, L. Glodzik, A. Pupi, D. Santi et al., PreClinical Detection of Alzheimer's Disease Using FDG-PET, with or without Amyloid Imaging, J. Alzheimers Dis. JAD, vol.20, pp.843-854, 2010.

D. Sole, A. Malaspina, S. Biasina, and A. M. , Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias, Funct. Neurol, vol.31, pp.205-215, 2017.

L. Mosconi, R. Mistur, R. Switalski, W. H. Tsui, L. Glodzik et al., FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease, Eur. J. Nucl. Med. Mol. Imaging, vol.36, pp.811-822, 2009.

K. A. Johnson, N. C. Fox, R. A. Sperling, and W. E. Klunk, Brain Imaging in Alzheimer Disease. Cold Spring Harb. Perspect. Med, vol.2, 2012.

W. Jagust, B. Reed, D. Mungas, W. Ellis, and C. Decarli, What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia, Neurology, vol.69, pp.871-877, 2007.

D. Silverman, G. W. Small, C. Y. Chang, C. S. Lu, M. Aburto et al., Positron Emission Tomography in Evaluation of Dementia: Regional Brain Metabolism and Long-term Outcome, JAMA, vol.286, pp.2120-2127, 2001.

L. Mosconi, W. H. Tsui, K. Herholz, A. Pupi, A. Drzezga et al., Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias, J. Nucl. Med. Off, 2008.

, Publ. Soc. Nucl. Med, vol.49, pp.390-398

C. Haense, K. Herholz, W. J. Jagust, and W. D. Heiss, Performance of FDG PET for detection of Alzheimer's disease in two independent multicentre samples (NEST-DD and ADNI), Dement. Geriatr. Cogn. Disord, vol.28, pp.259-266, 2009.

G. B. Frisoni, M. Bocchetta, G. Chételat, G. D. Rabinovici, M. J. De-leon et al., Imaging markers for Alzheimer disease, Neurology, vol.81, pp.487-500, 2013.

J. Dukart, K. Mueller, A. Horstmann, H. Barthel, H. E. Möller et al., Combined Evaluation of FDG-PET and MRI Improves Detection and Differentiation of Dementia, PLoS ONE, vol.6, 2011.

G. Chételat, F. Eustache, F. Viader, D. La-sayette, V. Pélerin et al., , pp.14-25, 2005.

L. Mosconi, D. Perani, S. Sorbi, K. Herholz, B. Nacmias et al., MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET, Neurology, vol.63, pp.2332-2340, 2004.

D. Silverman, G. W. Small, C. Y. Chang, C. S. Lu, M. De-aburto et al., Positron Emission Tomography in Evaluation of Dementia: Regional Brain Metabolism and Long-term Outcome, JAMA, vol.286, p.2120, 2001.

Y. Yuan, Z. Gu, and W. Wei, Fluorodeoxyglucose-Positron-Emission Tomography, Single-Photon Emission Tomography, and Structural MR Imaging for Prediction of Rapid Conversion to Alzheimer Disease in Patients with Mild Cognitive Impairment: A Meta-Analysis, Am. J. Neuroradiol, vol.30, pp.404-410, 2009.

M. J. De-leon, A. Convit, O. T. Wolf, C. Y. Tarshish, S. Desanti et al., Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-dglucose/positron-emission tomography (FDG/PET), Proc. Natl. Acad. Sci. U. S. A, vol.98, pp.10966-10971, 2001.

N. Smailagic, M. Vacante, C. Hyde, S. Martin, O. Ukoumunne et al., 18 F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI), 2015.

, Cochrane Database Syst. Rev, vol.1, p.10632

S. Morbelli, V. Garibotto, E. Giessen, J. Arbizu, G. Chételat et al., Medicine O behalf of the EA of N (2015) A Cochrane review on brain [<Superscript>18</Superscript>F]FDG PET in dementia: limitations and future perspectives, Eur. J. Nucl. Med. Mol. Imaging, vol.42, pp.1487-1491

V. Garibotto, K. Herholz, M. Boccardi, A. Picco, A. Varrone et al., Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework, Neurobiol. Aging, vol.52, pp.183-195, 2017.

P. Scheltens, D. Leys, F. Barkhof, D. Huglo, H. C. Weinstein et al., Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates, J. Neurol. Neurosurg. Psychiatry, vol.55, pp.967-972, 1992.

J. Ashburner and K. J. Friston, Voxel-Based Morphometry-The Methods, NeuroImage, vol.11, pp.805-821, 2000.
DOI : 10.1006/nimg.2000.0582

URL : http://www.stat.wisc.edu/~mchung/teaching/MIA/reading/VBM.ashburner.2000.pdf

G. B. Frisoni, N. C. Fox, C. R. Jack, P. Scheltens, and P. M. Thompson, The clinical use of structural MRI in Alzheimer disease, Nat. Rev. Neurol, vol.6, pp.67-77, 2010.

S. L. Risacher and A. J. Saykin, Neuroimaging and Other Biomarkers for Alzheimer's Disease: The Changing Landscape of Early Detection, Annu. Rev. Clin. Psychol, vol.9, pp.621-648, 2013.

E. J. Burton, R. Barber, E. B. Mukaetova-ladinska, J. Robson, R. H. Perry et al., Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis, Brain, vol.132, pp.195-203, 2009.

G. Karas, J. Sluimer, R. Goekoop, . Flier-w-van-der, . Rb et al., Amnestic Mild Cognitive Impairment: Structural MR Imaging Findings Predictive of Conversion to Alzheimer Disease, Am. J. Neuroradiol, vol.29, pp.944-949, 2008.

G. Chételat, B. Desgranges, B. Landeau, F. Mézenge, J. B. Poline et al., Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease, Brain, vol.131, pp.60-71, 2008.

I. Matsunari, M. Samuraki, W. Chen, D. Yanase, N. Takeda et al., Comparison of 18F-FDG PET and Optimized Voxel-Based Morphometry for Detection of Alzheimer's Disease: Aging Effect on Diagnostic Performance, J. Nucl. Med, vol.48, pp.1961-1970, 2007.

T. Kawachi, K. Ishii, S. Sakamoto, M. Sasaki, T. Mori et al., Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease, Eur. J. Nucl. Med. Mol. Imaging, vol.33, pp.801-809, 2006.

D. Santi, S. De-leon, M. J. Rusinek, H. Convit, A. Tarshish et al., Hippocampal formation glucose metabolism and volume losses in MCI and AD, Neurobiol. Aging, vol.22, pp.529-539, 2001.

V. Kljajevic, M. J. Grothe, M. Ewers, and S. Teipel, Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer's disease, Neurobiol. Aging, vol.35, pp.1973-1981, 2014.

W. E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist et al., Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B, Ann. Neurol, vol.55, pp.306-319, 2004.

M. D. Ikonomovic, W. E. Klunk, E. E. Abrahamson, C. A. Mathis, J. C. Price et al., Post-mortem correlates of in vivo PiBPET amyloid imaging in a typical case of Alzheimer's disease, Brain, vol.131, pp.1630-1645, 2008.

T. Varghese, R. Sheelakumari, J. S. James, and P. Mathuranath, A review of neuroimaging biomarkers of Alzheimer's disease. Neurol, Asia, vol.18, pp.239-248, 2013.

D. F. Wong, P. B. Rosenberg, Y. Zhou, A. Kumar, V. Raymont et al., Vivo Imaging of Amyloid Deposition in Alzheimer's Disease using the Novel Radioligand, vol.51, pp.913-920, 2010.

K. Lin, I. Hsiao, J. Hsu, C. Huang, K. Huang et al., Imaging characteristic of dual-phase (18)F-florbetapir (AV45/Amyvid) PET for the concomitant detection of perfusion deficits and betaamyloid deposition in Alzheimer's disease and mild cognitive impairment, 2016.

, J. Nucl. Med. Mol. Imaging, vol.43, pp.1304-1314

D. G. Clark, V. G. Wadley, P. Kapur, T. P. Deramus, B. Singletary et al., Lexical factors and cerebral regions influencing verbal fluency performance in MCI, Neuropsychologia, vol.54, pp.98-111, 2014.

V. L. Villemagne, K. Ong, R. S. Mulligan, G. Holl, S. Pejoska et al., Amyloid Imaging with 18FFlorbetaben in Alzheimer Disease and Other Dementias, J. Nucl. Med, vol.52, pp.1210-1217, 2011.

H. Barthel, H. Gertz, S. Dresel, O. Peters, P. Bartenstein et al., Cerebral amyloid-? PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study, Florbetaben Study Group, vol.10, pp.424-435, 2011.

R. Vandenberghe, K. Van-laere, A. Ivanoiu, E. Salmon, C. Bastin et al., 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial, Ann. Neurol, vol.68, pp.319-329, 2010.

Z. Cselényi, M. E. Jönhagen, A. Forsberg, C. Halldin, P. Julin et al., Clinical Validation of 18F-AZD4694, an Amyloid-?-Specific PET Radioligand, J. Nucl. Med, vol.53, pp.415-424, 2012.

A. M. Fagan, M. A. Mintun, R. H. Mach, S. Lee, C. S. Dence et al., Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans, Ann. Neurol, vol.59, pp.512-519, 2006.

S. Landau, B. Thomas, L. Thurfjell, M. Schmidt, R. Margolin et al., Amyloid PET imaging in Alzheimer's disease: A comparison of three radiotracers, Eur. J. Nucl. Med. Mol. Imaging, vol.41, pp.1398-1407, 2014.

E. Morris, A. Chalkidou, A. Hammers, J. Peacock, J. Summers et al., Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis, Eur. J. Nucl, 2016.

. Med, Mol. Imaging, vol.43, pp.374-385

A. Forsberg, H. Engler, O. Almkvist, G. Blomquist, G. Hagman et al., PET imaging of amyloid deposition in patients with mild cognitive impairment, Neurobiol. Aging, vol.29, pp.1456-1465, 2008.

P. Lewczuk, B. Mroczko, A. Fagan, and J. Kornhuber, Biomarkers of Alzheimer's disease and mild cognitive impairment: A current perspective, 2015.

, Adv. Med. Sci, vol.60, pp.76-82

M. Ceccaldi, T. Jonveaux, A. Verger, P. Krolak-salmon, C. Houzard et al., Alzheimers Dement. J. Alzheimers Assoc, vol.14, pp.293-305, 2018.

M. A. Mintun, G. N. Larossa, Y. I. Sheline, C. S. Dence, S. Y. Lee et al., 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease, Neurology, vol.67, pp.446-452, 2006.

W. J. Jansen, R. Ossenkoppele, D. L. Knol, B. M. Tijms, P. Scheltens et al., Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia, JAMA, vol.313, pp.1924-1938, 2015.

V. L. Villemagne, M. T. Fodero-tavoletti, C. L. Masters, and C. C. Rowe, Tau imaging: early progress and future directions, Lancet Neurol, vol.14, pp.114-124, 2015.

V. L. Villemagne and N. Okamura, Alzheimer's disease, and other neurodegenerative conditions, Curr. Opin, 2016.

. Neurobiol, , vol.36, pp.43-51

B. Hall, E. Mak, S. Cervenka, F. I. Aigbirhio, J. B. Rowe et al., In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings, Ageing Res. Rev, vol.36, pp.50-63, 2017.

L. Saint-aubert, L. Lemoine, K. Chiotis, A. Leuzy, E. Rodriguez-vieitez et al., Tau PET imaging: present and future directions, Mol. Neurodegener, vol.12, 2017.

A. Maass, S. Landau, S. L. Baker, A. Horng, S. N. Lockhart et al., Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease, NeuroImage, vol.157, pp.448-463, 2017.

N. Okamura, S. Furumoto, M. T. Fodero-tavoletti, R. S. Mulligan, R. Harada et al., Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET, Brain, vol.137, pp.1762-1771, 2014.

C. R. Jack, D. A. Bennett, K. Blennow, M. C. Carrillo, H. H. Feldman et al., A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers, Neurology, vol.87, pp.539-547, 2016.

C. R. Jack, D. S. Knopman, W. J. Jagust, R. C. Petersen, M. W. Weiner et al., Update on hypothetical model of Alzheimer's disease biomarkers, Lancet Neurol, vol.12, pp.207-216, 2013.

J. A. Hardy and G. A. Higgins, Alzheimer's disease: the amyloid cascade hypothesis, Science, vol.256, pp.184-185, 1992.

D. S. Knopman, C. R. Jack, H. J. Wiste, S. D. Weigand, P. Vemuri et al., Brain Injury Biomarkers Are Not Dependent on ?-amyloid in Normal Elderly, Ann. Neurol, vol.73, pp.472-480, 2013.

C. R. Jack, H. J. Wiste, S. D. Weigand, D. S. Knopman, V. Lowe et al., Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity, Neurology, vol.81, pp.1732-1740, 2013.
DOI : 10.1212/01.wnl.0000435556.21319.e4

URL : http://n.neurology.org/content/81/20/1732.full.pdf

C. R. Jack and D. M. Holtzman, Biomarker Modeling of Alzheimer's Disease, Neuron, vol.80, pp.1347-1358, 2013.

C. R. Jack, T. M. Therneau, H. J. Wiste, S. D. Weigand, D. S. Knopman et al., Rates of transition between amyloid and neurodegeneration biomarker states and to dementia among non-demented individuals: a population-based cohort study, Lancet Neurol, vol.15, pp.56-64, 2016.

W. Jagust, Vulnerable Neural Systems and the Borderland of Brain Aging and Neurodegeneration, Neuron, vol.77, pp.219-234, 2013.

P. Alexopoulos, L. Kriett, B. Haller, E. Klupp, K. Gray et al., Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease, Alzheimers Dement, vol.10, pp.684-689, 2014.

F. L. Besson, R. L. Joie, L. Doeuvre, M. Gaubert, F. Mézenge et al., Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease, J. Neurosci, vol.35, pp.10402-10411, 2015.

A. Caroli and G. B. Frisoni, The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort, Neurobiol. Aging, vol.31, pp.1263-1274, 2010.

K. Meguro, C. Lemestric, B. Landeau, B. Desgranges, F. Eustache et al., Relations between hypometabolism in the posterior association neocortex and hippocampal atrophy in Alzheimer's disease: a PET/MRI correlative study, J. Neurol. Neurosurg. Psychiatry, vol.71, pp.315-321, 2001.

D. S. Karow, L. K. Mcevoy, C. Fennema-notestine, D. J. Hagler, R. G. Jennings et al., Relative Capability of MR Imaging and FDG PET to Depict Changes Associated with Prodromal and Early Alzheimer Disease, Radiology, vol.256, pp.932-942, 2010.

A. Aziz, B. Giusiano, S. Joubert, L. Duprat, M. Didic et al., Difference in imaging biomarkers of neurodegeneration between early and late-onset amnestic Alzheimer's disease, Neurobiol. Aging, vol.54, pp.22-30, 2017.

M. F. Folstein, S. E. Folstein, and P. R. Mchugh, Mini-mental state": A practical method for grading the cognitive state of patients for the clinician, J. Psychiatr. Res, vol.12, pp.189-198, 1975.

B. Dubois, A. Slachevsky, I. Litvan, and B. Pillon, The FAB: a Frontal Assessment Battery at bedside, Neurology, vol.55, pp.1621-1626, 2000.

R. M. Reitan, The relation of the trail making test to organic brain damage, J. Consult. Psychol, vol.19, pp.393-394, 1955.

E. Barbeau, M. Didic, E. Tramoni, O. Felician, S. Joubert et al., Evaluation of visual recognition memory in MCI patients, Neurology, vol.62, pp.1317-1322, 2004.

C. Thomas-antérion and M. Puel, La mémoire collective, mémoire des événements publics et des célébrités : les batteries EVE30 et TOP30, 2006.

G. Deloche and D. Hannequin, , vol.80, 1997.

A. L. Benton, N. R. Varney, K. Hamsher, and . Des, Visuospatial Judgment: A Clinical Test, Arch. Neurol, vol.35, pp.364-367, 1978.
DOI : 10.1001/archneur.1978.00500300038006

A. Rey, Test for the examination of constructional apraxia, Rev. Neurol, vol.102, pp.653-656, 1960.

F. Mahieux-laurent, C. Fabre, E. Galbrun, A. Dubrulle, and C. Moroni, Validation d'une batterie brève d'évaluation des praxies gestuelles pour consultation Mémoire. Évaluation chez 419 témoins, 127 patients atteints de troubles cognitifs légers et 320 patients atteints d'une démence, 2009.
DOI : 10.1016/j.neurol.2008.11.016

G. Chételat, Multimodal Neuroimaging in Alzheimer's Disease: Early Diagnosis, Physiopathological Mechanisms, and Impact of Lifestyle, J. Alzheimers Dis. JAD, 2018.

K. Chen, N. Ayutyanont, J. Langbaum, A. S. Fleisher, C. Reschke et al., Correlations between FDG PET glucose uptake-MRI gray matter volume scores and apolipoprotein E ?4 gene dose in cognitively normal adults: a cross-validation study using voxel-based multi-modal partial least squares, Neuroimage, vol.60, pp.2316-2322, 2012.

B. Olsson, R. Lautner, U. Andreasson, A. Öhrfelt, E. Portelius et al., CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis, Lancet Neurol, vol.15, pp.673-684, 2016.

C. G. Schipke, N. Koglin, S. Bullich, L. K. Joachim, B. Haas et al., Correlation of florbetaben PET imaging and the amyloid peptide Aß42 in cerebrospinal fluid, Psychiatry Res, vol.265, pp.98-101, 2017.

P. Edison, H. A. Archer, R. Hinz, A. Hammers, N. Pavese et al., Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study, Neurology, vol.68, pp.501-508, 2007.

V. J. Lowe, S. D. Weigand, M. L. Senjem, P. Vemuri, L. Jordan et al., Association of hypometabolism and amyloid levels in aging, normal subjects, Neurology, vol.82, pp.1959-1967, 2014.

G. N. Bischof, F. Jessen, K. Fliessbach, J. Dronse, J. Hammes et al., Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease, 2016.

, 1 : atrophie limitée-hypométabolisme limité ; 2 : atrophie limitée-hypométabolisme étendu 3 : atrophie étendue-hypométabolisme limité, Transl. Neurol, vol.3, pp.934-939